Traditional drug development has focused primarily on protein targets. This reflects the diverse structural and catalytic roles of cellular proteins that provide for opportune targets in metabolic and infectious disease. The complexity of protein structure also affords an opportunity for highly selective recognition by organic molecules, using spatial and bonding constraints to map drugs to protein targets. Such approaches have been successfully used in the treatment of disease states that derive from structural or catalytic perturbations of enzyme function. The role of inorganic chemistry in drug development has been severely limited and metal ions have been recruited into drug design only peripherally, either as a target for binding of an organic ligand through coordination to the metal cofactor of a metalloprotein, or, rarely, as an active complex. DNA has also served as a focus of investigation for drug development, and in this case cisplatin is an example of one of the most prominent applications of inorganic complexes in the treatment of disease. However, DNA poses significant problems with regard to recognition of specific sequences. Typically this requires the use of complementary oligonucleotides with an attached metal complex and such an approach severely limits the scope of what can be usefully developed. A third target, RNA, has not previously received the intensity of recognition afforded to the other two, although many structural and chemical features of RNA make it attractive as a drug target. Most important, there is no cellular repair mechanism for RNA As a result of the many disease states caused by RNA viruses, compounds that are capable of specific or selective binding to RNA should be considered in developing effective chemotherapeutic treatments. Copper aminoglycosides are demonstrated to be highly efficient cleavage catalysts for DNA and RNA targets. Such catalysts mediate both oxidative and hydrolytic pathways and their cleavage reactions display enzymelike Michaelis-Menten kinetic behavior. Both in vitro and in vivo cleavage of RNA targets have been demonstrated, and this proposal seeks to expand our understanding of the chemical mechanisms underlying the selective binding and cleavage of RNA targets and improve develop their use as bona fide inorganic drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM063740-04
Application #
7068152
Study Section
Metallobiochemistry Study Section (BMT)
Program Officer
Preusch, Peter C
Project Start
2003-06-01
Project End
2009-05-31
Budget Start
2006-06-01
Budget End
2009-05-31
Support Year
4
Fiscal Year
2006
Total Cost
$234,055
Indirect Cost
Name
Ohio State University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Hocharoen, Lalintip; Cowan, James A (2009) Metallotherapeutics: novel strategies in drug design. Chemistry 15:8670-6
Bradford, Seth; Kawarasaki, Yuta; Cowan, J A (2009) Copper.Lys-Gly-His-Lys mediated cleavage of tRNA(Phe): studies of reaction mechanism and cleavage specificity. J Inorg Biochem 103:871-5
Gokhale, Nikhil H; Bradford, Seth; Cowan, J A (2008) Catalytic inactivation of human carbonic anhydrase I by a metallopeptide-sulfonamide conjugate is mediated by oxidation of active site residues. J Am Chem Soc 130:2388-9
Gokhale, Nikhil H; Bradford, Seth; Cowan, J A (2007) Stimulation and oxidative catalytic inactivation of thermolysin by copper.Cys-Gly-His-Lys. J Biol Inorg Chem 12:981-7
Jin, Yan; Lewis, Mark A; Gokhale, Nikhil H et al. (2007) Influence of stereochemistry and redox potentials on the single- and double-strand DNA cleavage efficiency of Cu(II) and Ni(II) Lys-Gly-His-derived ATCUN metallopeptides. J Am Chem Soc 129:8353-61
Jin, Yan; Cowan, J A (2007) Cellular activity of Rev response element RNA targeting metallopeptides. J Biol Inorg Chem 12:637-44
Gokhale, Nikhil H; Cowan, J A (2006) Metallopeptide-promoted inactivation of angiotensin-converting enzyme and endothelin-converting enzyme 1: Toward dual-action therapeutics. J Biol Inorg Chem 11:937-47
Jin, Yan; Cowan, J A (2006) Targeted cleavage of HIV rev response element RNA by metallopeptide complexes. J Am Chem Soc 128:410-1
Gokhale, Nikhil H; Cowan, J A (2005) Inactivation of human angiotensin converting enzyme by copper peptide complexes containing ATCUN motifs. Chem Commun (Camb) :5916-8
Jin, Yan; Cowan, J A (2005) DNA cleavage by copper-ATCUN complexes. Factors influencing cleavage mechanism and linearization of dsDNA. J Am Chem Soc 127:8408-15